Larch arabinogalactan from Larix laricina and Larix occidentalis has been approved by the Australian Authorities and is now listed as Therapeutic Goods

Basel, Switzerland, July 21st, 2008 – The Australian Authorities announced on July 8th that Larch arabinogalactan is now approved as a therapeutically active ingredient for oral use. Three requirements have to be met for approval all of which are fulfilled by Lonza’s active ingredient: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient arabinogalactan (Larix) is greater than or equal to 85%; and the maximum recommended daily dose of the ingredient arabinogalactan (Larix) is not to exceed 15 grams. This announcement can be found at

In Australia, Larch arabinogalactan had been approved before as a food additive only. “This new approval is good news, as Larch arabinogalactan, which we sell as an ingredient for use in products positioned for digestive health benefits under the brand name, FiberAid™, was not approved for such applications in Australia”, comments René Blum, Global Head of Regulatory Affairs for the Nutritional Ingredients at Lonza. FiberAid™ is self-affirmed GRAS (Generally Recognized As Safe) with FDA notification. In the European Union, Arabinogalactan is listed in the Novel Food catalogue published on June 17th, 2008 for use as a food supplement.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.